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Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are an effective and common treatment for chronic
pain disorders, but long-term use is associated with risk of potentially life-threatening gastrointestinal adverse
events (AEs). The proton pump inhibitor esomeprazole has been found to be effective for gastroprotection in
NSAID users, but few long-term studies have been conducted in Japan.
Methods: This was an open-label, multicentre, single-arm, prospective 1-year study of treatment with esomeprazole
(20 mg once daily) in Japanese patients (aged ≥20 years) with endoscopic evidence of previous peptic ulcer and
receiving daily oral NSAID therapy (at a stable dose) for a chronic condition. Eligibility was not dictated by type of
oral NSAID. The primary objective was to determine long-term safety and tolerability of esomeprazole. Efficacy for
prevention of peptic ulcers was also determined (Kaplan-Meier method). All statistical analyses were descriptive.
Results: A total of 130 patients (73.1% women, mean age 62.1 years, 43.8% Helicobacter pylori-positive) received
treatment with esomeprazole in addition to long-term NSAID therapy (most commonly for rheumatoid arthritis
[n=42] and osteoarthritis [n=34]). Loxoprofen, meloxicam and diclofenac were the most commonly used NSAIDs;
cyclo-oxygenase (COX)-2 selective agents were used by 16.2% of patients (n=21). Long-term compliance with
esomeprazole (capsule counts) was >75% for the majority of patients. Although 16.9% of patients (n=22)
experienced AEs judged to be possibly related to treatment with esomeprazole, they were mostly mild and
transient. The most commonly reported possibly treatment-related AEs were abnormal hepatic function, headache,
increased γ-glutamyltransferase levels and muscle spasms (2 patients each). Overall, 95.9% (95% confidence interval:
92.3, 99.4) of patients remained ulcer free at 1 year.
Conclusion: Long-term treatment with esomeprazole (20 mg once daily) is well tolerated and efficacious for
preventing ulcer recurrence in Japanese NSAID users with a history of peptic ulcer.
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Chronic pain conditions, such as osteoarthritis and rheu-
matoid arthritis, are common in Japan. For example, the
prevalence of gonarthrosis or gonarthritis among women
in Japan is 36–63%, depending on age [1], and some
320,000 Japanese individuals are affected by rheumatoid
arthritis according to a 2002 survey [2]. Non-steroidal
anti-inflammatory drugs (NSAIDs) provide effective pain
management for patients with such conditions [3], and are
widely prescribed in Japan and other Asian countries [4,5].
While effective for relief of pain, the long-term use of
NSAIDs may cause gastrointestinal (GI) adverse events
(AEs) ranging from mild upper GI symptoms such as
dyspepsia [6] to peptic ulcers, which can lead to life-
threatening complications if the ulcers perforate or
haemorrhage [6,7]. A pooled analysis of 21 randomised,
parallel-group studies of celecoxib and non-selective
NSAIDs, for example, identified GI symptoms (abdominal
pain, dyspepsia, nausea, diarrhoea and flatulence) in 16% of
patients taking celecoxib and around 20–24% of those ta-
king diclofenac, ibuprofen or naproxen [6]. With regard to
the risk of peptic ulcers, a study of patients with osteoarth-
ritis found that up to 17% of patients developed such
lesions within 12 weeks of commencing treatment with
non-selective NSAIDs such as ibuprofen and diclofenac [8].
This compares with a background incidence of 3.3% in a
general population, based on a meta-analysis of the placebo
treatment arms of 36 clinical trials of NSAIDs [9]. Risk fac-
tors for upper GI events among NSAID users are nume-
rous, and include older age, a history of previous GI events
(e.g. bleeds) and use of higher NSAID doses [10,11].
Minimising the risk of potentially serious GI events in
long-term NSAID users is clearly appropriate, especially
for those patients at increased risk. The proton pump in-
hibitor (PPI) esomeprazole has been shown to be effica-
cious in the prevention of peptic ulcers and upper GI
symptoms related to NSAID use in European, North
American and Japanese patients [12-14], but few long-
term studies have been conducted in the corresponding
Japanese population. The present study therefore investi-
gated the safety and tolerability of long-term treatment
with esomeprazole 20 mg in Japanese patients with an
endoscopically-confirmed history of peptic ulcer who
were also receiving daily NSAID therapy. Efficacy of
esomeprazole for prevention of peptic ulcers and gastro-
intestinal symptoms was also determined.
Methods
Study design
This was an open-label, multicentre, single-arm, prospect-
ive study in Japanese patients with a history of peptic ulcer
receiving daily NSAID therapy (ClinicalTrials.gov identi-
fier: NCT00595517; study code: D961HC00005). The
study was conducted in accordance with the ethicalprinciples of the Declaration of Helsinki, ICH/Good Clin-
ical Practice and good clinical practice regulatory require-
ments in Japan [15]. The study protocol was approved by
the Institutional Review Board of Shirakawa Hospital,
Fukushima and approved by an independent institutional
review board or research ethics committee at each partici-
pating centre. Written informed consent was a require-
ment for patients to enter the study, which was conducted
between October 2007 and September 2009.
Patients and treatment
Japanese men and women aged ≥20 years with a history of
peptic ulcer were recruited to the study. History of peptic
ulcer was defined as evidence of ulcer scarring during en-
doscopy performed within 2 weeks of enrolment. Scarring
was evaluated according to the Sakita/Miwa classification
[16], i.e. ‘red scar’ (S1): hyperaemia remains in the centre of
the scar; ‘white scar’ (S2): hyperaemia in the scar has
disappeared, turning into the same colour as adjacent mu-
cosa. Patients were also required to have a chronic condi-
tion (e.g. rheumatoid arthritis, osteoarthritis) that neces-
sitated daily oral NSAID treatment (≥5 days/week) at a
stable dose for the duration of the study. Eligibility was not
dictated by type of oral NSAID. Use of additional oral/top-
ical NSAIDs was permitted to maintain patient wellbeing.
Exclusion criteria included severe liver or renal disease, ab-
normal liver or kidney function tests, a history of malignant
disease or other defined conditions including Barrett’s
esophagus, esophagitis, pancreatitis, uncontrolled diabetes
mellitus or severe cardiovascular or cerebrovascular disease.
Presence of active ulcer was not permitted, nor was con-
tinuous use of pre-specified concomitant medications in-
cluding anticoagulant/antiplatelet therapy (including aspirin
<325 mg/day), PPIs, mucosal protectants, H2-receptor an-
tagonists, antacids or prostaglandin analogues indicated for
peptic ulcer. In accordance with the study protocol, treat-
ment with Helicobacter pylori-eradication therapy was also
not permitted after enrolment to avoid the potential
confounding effect on ulcer recurrent rates. Women of
child-bearing potential had to have a negative pregnancy
test at the screening visit, and to use effective contraception
during the study.
Patients received one capsule of esomeprazole 20 mg or-
ally once daily (od), after breakfast, for 52 weeks in addition
to physician-prescribed NSAID therapy. Compliance with
esomeprazole treatment was determined by checking the
number of remaining capsules returned at regular clinic
visits (every 4–8 weeks). Subjects were also asked to record
their daily NSAID use in a diary, and study investigators
checked the NSAID treatment diary at each clinic visit.
Outcomes
The primary objective was the assessment of safety and
tolerability of esomeprazole 20 mg od during 52 weeks
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clinical laboratory tests (haematology, biochemistry and
urinalysis) and measurement of vital signs at each clinic
visit. Information on AEs (spontaneously reported, and in
response to open questioning) was collected according to
standard regulatory requirements, an AE being defined as
the development of an undesirable medical condition (or
the deterioration of a pre-existing medical condition) fol-
lowing or during exposure to study medication. In this re-
gard, an undesirable medical condition was considered to
be symptoms, signs or the abnormal results of any investi-
gation. AEs were evaluated by investigators in terms of
seriousness, maximum intensity (mild, moderate or se-
vere), outcome and possible causality with study medica-
tion. A genetic test was also completed for each patient, in
order to determine cytochrome P450 (CYP) 2C19 geno-
type; based on the result of this test, patients were classi-
fied as ‘extensive metabolisers’ (homo- and hetero- types)
or ‘poor metabolisers’. The latter subgroup was defined as
those with *2 and *3 variant alleles. Such tests were com-
pleted by a central laboratory (Mitsubishi Chemical
Medience Corporation, Tokyo, Japan).
The secondary objective was to assess the efficacy of
esomeprazole 20 mg od by the following evaluations:
 Endoscopic evidence of peptic ulcer and severity of
gastric mucosal lesions (evaluated by modified
LANZA score [17], if present) at weeks 4, 12, 24
and 52.
 Presence and severity (mild, moderate or severe) of
investigator-assessed pre-specified dyspeptic
symptoms every 4 weeks to week 52.
With regard to the assessment of gastric mucosal
lesions, patients were assigned a modified LANZA score
as follows: absence of haemorrhage and erosion (0); one
haemorrhage or erosion (+1); 2–10 haemorrhages or
erosions (+2); 11–25 haemorrhages or erosions (+3);
and >25 haemorrhages, erosions or an ulcer (+4). In
terms of the symptom assessment, patients were asked
to report on the presence and severity of specific symp-
toms (epigastric pain or discomfort, abdominal fullness,
nausea/vomiting, heartburn and anorexia) during the
7 days before clinic visits.
Statistical analyses
All analyses were descriptive. The safety evaluation (pri-
mary objective) comprised all patients who had taken at
least one dose of study medication and from whom any
post-dose data were available (safety analysis set). Effi-
cacy outcomes (secondary objective) were analysed for
the full analysis set (FAS), which consisted of patients
who took at least one dose of study medication and who
had no active peptic ulcer at baseline. Peptic ulcer-freerates (and 95% confidence intervals [CIs]) were esti-
mated using the Kaplan-Meier method. For the purposes
of this analysis, an event was defined as endoscopy-
confirmed peptic ulcer; time-to-event comprised the time
between the date of initial administration and the date of
event occurrence. The last endoscopy test day was the
data cut-off for patients who did not develop ulcer(s)
throughout the study period (the last-observation-carried-
forward approach was not used). Observed ulcer-free rates
were also recorded according to endoscopic evaluation,
and additional analyses were completed to evaluate the ef-
fect of risk factors on ulcer-free rates. Supplementary
efficacy analyses were completed according to an inde-
pendent review of each patient’s endoscopic images by a
Central Evaluation Committee (Y.K. and H.M.). The
change of modified LANZA score and symptoms was
evaluated using shift tables.
In view of the study design and duration, a sample size
of over 100 completing patients was deemed sufficient
to meet the primary objectives of the study.
Results
Patients
A total of 395 patients were screened for inclusion, of
whom 265 patients were not registered for the study be-
cause of non-eligibility (n=247) or voluntary discontinu-
ation by patients (n=18). Almost all of the non-eligible
patients had no evidence of ulcer scarring during endo-
scopic assessment, and thereby did not meet the study in-
clusion criterion (history of peptic ulcer). A total of 130
patients therefore entered the study and received treatment
with esomeprazole. Enrolled patients were mainly women
(73.1%), and the mean age was 62.1 years (Table 1). More
than half (51.5%) of the patients were aged 65 years or
older, and 43.8% were H. pylori-positive (serology test). The
most frequent diagnoses that necessitated long-term
NSAID therapy were rheumatoid arthritis (n=42, 32.3%)
and osteoarthritis (n=34, 26.2%); the remaining patients
had other chronic conditions (mostly lumbago and cervical
spondylitis; n=54, 41.5%). Loxoprofen, meloxicam and
diclofenac were the most commonly used NSAIDs at base-
line (40.0%, 17.7% and 11.5%, respectively). COX-2 selective
NSAIDs (celecoxib, etodolac or nabumetone) were used by
16.2% of patients (n=21). Overall, few patients were using
two or more NSAIDs at baseline (n=5, 3.8%). Some 24.6%
of patients (n=32) were receiving concomitant treatment
with corticosteroids, most commonly prednisolone. A total
of 22 patients (16.9%) were CYP2C19 poor metabolisers.
Compliance with daily esomeprazole and NSAID ther-
apy during the course of the study was good (99% of pa-
tients took more than 75% [esomeprazole] or 70%
[NSAIDs] of prescribed medication as instructed).
A total of 116 patients completed the study (including
5 patients with recurrent ulcer). The main reasons for
Table 1 Baseline characteristics of patients (full analysis set)




Mean±SD (range), years 62.1±12.6 (32–84)
≤64 years 63 (48.5)
≥65 to ≤74 years 43 (33.1)
≥75 years 24 (18.5)
Type of arthritic disease
Rheumatoid arthritis 42 (32.3)
Osteoarthritis 34 (26.2)
Other chronic condition 54 (41.5)
Duration of disease, mean±SD (range), years 6.0±6.9 (0–38)
Helicobacter pylori infection (serology test) 57 (43.8)
Use of corticosteroids 32 (24.6)
CYP2C19 genotype
Poor metaboliser 22 (16.9)
Hetero extensive metaboliser 68 (52.3)
Homo extensive metaboliser 40 (30.8)
Values are presented as number of patients (%), unless otherwise stated.
Abbreviation: CYP2C19, cytochrome P450 2C19.
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voluntary patient withdrawal (n=4). A summary of pa-
tient flow through the study is shown in Figure 1.
Primary objective: safety and tolerability
Overall, 123 patients (94.6%) reported at total of 564 AEs
during the 52-week treatment period. No time-related
trends were generally apparent, and the majority of AEs
were of mild-to-moderate intensity and non-serious. The
most commonly reported AEs were nasopharyngitis, ag-
gravation of underlying rheumatoid arthritis and upperFigure 1 Patient flow.abdominal pain. Six patients (4.6%) discontinued from the
study because of AEs, including one patient with an event
(erosive gastritis) that was considered related to the study
treatment (Table 2).
AEs possibly related to treatment, as judged by the in-
vestigator, were experienced by 16.9% of patients (n=22).
These were mostly of mild intensity, transient and only
single occurrences. The most commonly reported pos-
sibly treatment-related AEs were abnormal hepatic func-
tion, headache, increased γ-glutamyltransferase levels
and muscle spasms (2 patients each) (Table 3).
There were no deaths and no clinically important
changes in laboratory test variables or vital signs consist-
ent with safety concern during the 52-week study.
Secondary objective: efficacy
Overall, the majority of FAS patients remained free of pep-
tic ulcers during the study; the estimated ulcer-free rate at
1 year was 95.9% (95% CI 92.3, 99.4; Figure 2). Observed
ulcer-free rates at weeks 4, 12, 24 and 52 were 100% (130/
130), 97.7% (127/130), 96.9% (126/130) and 96.2% (125/
130), respectively. All 5 patients (4 women and 1 man)
who did not remain ulcer-free developed gastric ulcers.
Clinical characteristic of these cases included one patient
with concomitant use of corticosteroids and another pa-
tient with confirmed H. pylori infection (serology test).
Ulcer-free rates at 1 year, by demographic or other patient
characteristics at baseline, are shown in Table 4. Similar
results were apparent for the efficacy analysis of the Cen-
tral Evaluation Committee (data not shown).
Shift tables showed that the majority of patients expe-
rienced an improvement in modified LANZA score dur-
ing the course of the study (Table 5).
While there was a very low incidence of dyspeptic symp-
toms both at baseline and during the course of the
Table 2 Number of patients (%) with at least one adverse
event (AE), by time interval (safety analysis set)







Any AEa 105 (80.8) 93 (80.2) 123 (94.6)
Nasopharyngitis 26 (20.0) 22 (19.0) 38 (29.2)
Rheumatoid arthritis
aggravated
13 (10.0) 4 (3.4) 17 (13.1)
Upper abdominal pain 8 (6.2) 8 (6.9) 14 (10.8)
Constipation 7 (5.4) 5 (4.3) 12 (9.2)
Diarrhoea 6 (4.6) 5 (4.3) 11 (8.5)
Stomach discomfort 6 (4.6) 4 (3.4) 10 (7.7)
Osteoarthritis 4 (3.1) 5 (4.3) 9 (6.9)
Headache 6 (4.6) 2 (1.7) 8 (6.2)
Nausea 0 8 (6.9) 8 (6.2)
Anorexia 3 (2.3) 4 (3.4) 7 (5.4)
Arthralgia 3 (2.3) 4 (3.4) 7 (5.4)
Contusion 4 (3.1) 4 (3.4) 7 (5.4)
Hypertension 4 (3.1) 3 (2.6) 7 (5.4)
Stomatitis 2 (1.5) 5 (4.3) 7 (5.4)
Vomiting 3 (2.3) 4 (3.4) 7 (5.4)
Severe AEs 2 (1.5) 1 (0.9) 3 (2.3)
Non-fatal serious AEs 13 (10.0) 5 (3.8) 18 (13.8)
AEs leading to treatment
discontinuationb
5 (3.8) 1 (0.9) 6 (4.6)
aOnly events reported for >5% of patients are listed. Information on AEs was
collected according to standard regulatory requirements, an AE being defined
as the development of an undesirable medical condition (or the deterioration
of a pre-existing medical condition) following or during exposure to study
medication. In this regard, an undesirable medical condition was considered
to be symptoms, signs or the abnormal results of any investigation.
bIncluding erosive gastritis (n=2), cerebral infarction (n=1), sore throat (n=1),
lung tumour (n=1) and influenza A virus infection (n=1).
Table 3 Number of patients (%) with at least one possibly
treatment-related adverse event (AE) (safety analysis set)
Esomeprazole 20 mg
once daily (n=130)
Possibly treatment-related AEsa 22 (16.9)
Abnormal hepatic function 2 (1.5)
Headache 2 (1.5)
Increased GGT levels 2 (1.5)
Muscle spasms 2 (1.5)
Anorexia 1 (0.8)
Asthma 1 (0.8)
Benign skin neoplasm 1 (0.8)
Constipation 1 (0.8)
Decreased neutrophil count 1 (0.8)
Decreased platelet count 1 (0.8)
Dysgeusia 1 (0.8)
Dysphagia 1 (0.8)
Erosive gastritis 1 (0.8)
Erysipelas 1 (0.8)
Esophageal candidiasis 1 (0.8)
Gastric polyps (fundic gland polyp) 1 (0.8)
Hypertension 1 (0.8)
Increased ALT levels 1 (0.8)
Increased blood CPK levels 1 (0.8)
Increased blood urea 1 (0.8)
Nummular eczema 1 (0.8)
Pneumonia 1 (0.8)
Pruritus 1 (0.8)
Stomach discomfort 1 (0.8)
Stomatitis 1 (0.8)
Upper abdominal pain 1 (0.8)
aInformation on AEs was collected according to standard regulatory
requirements, an AE being defined as the development of an undesirable
medical condition (or the deterioration of a pre-existing medical condition)
following or during exposure to study medication. In this regard, an
undesirable medical condition was considered to be symptoms, signs or the
abnormal results of any investigation.
Abbreviations: ALT, alanine aminotransferase; CPK, creatine phosphokinase;
GGT, γ-glutamyltransferase.
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tended to decrease during long-term treatment with
esomeprazole (Table 6).
Discussion
Esomeprazole 20 mg od, administered over 1 year, had a
favourable safety profile and was well tolerated in Japa-
nese NSAID users with a history of peptic ulcer. Such
findings are consistent with another recent study of
treatment with lansoprazole (15 mg od) in long-term
NSAID users in Japan [18]. Notably, the nature and fre-
quency of AEs with esomeprazole in the present study
was generally consistent throughout the 1-year treat-
ment duration, and only a small proportion of patients
experienced AEs that were assessed as possibly drug-
related by the investigator. Moreover, few serious AEs
were reported.
In terms of efficacy (secondary objective), esomeprazole
proved efficacious in preventing the recurrence of pepticulcers in this at-risk patient population, with an overall es-
timated ulcer-free rate after 1 year of 95.9%. Such findings
compare favourably with a similar study of lansoprazole in
Japanese long-term NSAID users and a history of peptic
ulcer, in which the estimated ulcer-free rate after 1 year
was somewhat lower at 87.3% [18]. Moreover, there was a
trend for a reduction in endoscopic GI lesions (modified
LANZA score) in the present study, and few patients ex-
perienced dyspeptic symptoms during study treatment.
These results, together with the favourable safety and tol-
erability findings, are consistent with previous long-term
studies of esomeprazole for prevention of pre-specified GI
symptoms and peptic ulcers in European and North
American patients receiving NSAIDs [12,13]. Indeed, the
Figure 2 Kaplan-Meier estimated rate of sustained ulcer-free status over 1 year (full analysis set).
Table 4 Kaplan-Meier estimated sustained ulcer-free rates
(95% confidence interval) at 52 weeks, presented by
patient subgroup (full analysis set)
Subgroup Esomeprazole 20 mg
once daily (n=130)
Sex
Men (n=35) 97.0% (91.1, 100)
Women (n=95) 95.5% (91.1, 99.8)
Age
≤64 years (n=63) 96.7% (92.2, 100)
≥65 to ≤74 years (n=43) 92.3% (83.9, 100)
≥75 years (n=24) 100% (100, 100)
Helicobacter pylori infection
Positive (n=57) 98.1% (94.3, 100)
Negative (n=73) 94.3% (88.8, 99.7)
Use of corticosteroids
Yes (n=32) 96.7 (90.2, 100)
No (n=98) 95.6 (91.4, 99.8)
Type of NSAID at baseline
COX-2-selective (n=21)a 94.7% (84.7, 100)
Non-selective (n=109) 96.1% (92.3, 99.8)
CYP2C19 genotype
Poor metaboliser (n=22) 95.5% (86.8, 100)
Hetero extensive metaboliser (n=68) 93.8% (87.9, 99.7)
Homo extensive metaboliser (n=40) 100% (100, 100)
aIncluding celecoxib, etodolac and nabumetone.
Abbreviations: COX, cyclo-oxygenase; CYP2C19, cytochrome P450 2C19;
NSAID, non-steroidal anti-inflammatory drug.
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1-year study (95.9%) is better than those seen in the
placebo-controlled, 6-month VENUS and PLUTO studies
(ulcer-free rates of 94.7% and 94.8%, respectively; life-table
estimates) [13]. A double-blind, randomised placebo-
controlled trial conducted in Japan also showed superior
efficacy of esomeprazole in preventing NSAID-related
ulcer recurrence compared with Western studies [14].
In accordance with earlier studies [13], we found that
esomeprazole seemed to be similarly efficacious for pre-
vention of peptic ulcers irrespective of the type of NSAID
that the patient was being treated with (non-selective or
COX-2 selective), although patient numbers were small.
Unfortunately, we were not able to evaluate the efficacy of
esomeprazole according to the duration of NSAID treat-
ment prior to study start, as such information was not col-
lected during baseline assessments. This represents a
potential study limitation, as duration of prior NSAIDTable 5 Number of patients by modified LANZA scorea of
the severity of gastric mucosal lesions at study end,
stratified by baseline score (full analysis set)
Baseline
Study end 0 +1 +2 +3 +4
0 40 10 28 4 0
+1 7 2 8 0 0
+2 5 2 11 2 0
+3 1 0 2 0 1
+4 1 0 3 1 2
aAbsence of haemorrhage and erosion (0); one haemorrhage or erosion (+1);
2–10 haemorrhages or erosions (+2); 11–25 haemorrhages or erosions (+3):
>25 haemorrhages, erosions or an ulcer (+4). Bold highlighted number in cell
signify improvement between baseline and study end.
Table 6 Number of patients with dyspeptic symptoms at
baseline and study end, stratified by baseline severity of
symptoms (full analysis set)
Symptom Baseline
Study end None Mild–Severe
Epigastric pain None 100 18
Mild–Severe 8 4
Stomach discomfort None 102 14
Mild–Severe 5 9
Abdominal fullness None 100 18
Mild–Severe 4 8
Nausea/vomiting None 116 8
Mild–Severe 4 2
Heartburn None 112 14
Mild–Severe 3 1
Anorexia None 111 10
Mild–Severe 7 2
Sugano et al. BMC Gastroenterology 2013, 13:54 Page 7 of 9
http://www.biomedcentral.com/1471-230X/13/54treatment could impact on the risk of ulcer recurrence. H.
pylori status did not seem to substantially impact the
therapeutic efficacy of esomeprazole (as also observed for
lansoprazole in a similar Japanese population [18]), and
this is consistent with findings showing that eradication of
this pathogen does not prevent recurrent ulcers in NSAID
users [19]. Notably, our study population included a larger
proportion of H. pylori-positive patients (43.8%) than com-
parable studies in Western populations (10–20%) [12,13].
Esomeprazole is mainly metabolised by CYP2C19 [20],
which is subject to genetic polymorphism. Consequently,
we performed genetic testing of CYP2C19 genotype in
order to determine whether this influenced long-term effi-
cacy of esomeprazole for prevention of peptic ulcers in our
at-risk Japanese population. Overall, CYP2C19 genotype
did not indicate any major impact on the gastroprotective
efficacy of esomeprazole, as the estimated ulcer-free rates
were similar for all CYP2C19 genotypes. While the results
are limited by the small number of patients, they are in
agreement with previous findings that esomeprazole-
mediated healing of reflux (erosive) esophagitis is unrelated
to CYP2C19 genotype [21].
We observed a low incidence of dyspeptic symptoms
during the present study, which is consistent with findings
elsewhere that esomeprazole provides sustained relief
from such symptoms in long-term NSAID users [12].
However, it should be noted that few patients reported
such symptoms at baseline; for example, only 18 patients
(13.8%) reported epigastric pain with NSAID therapy. This
may be somewhat discordant from studies in Western
populations that have reported upper GI symptoms, such
as dyspepsia, in as many as 40% of NSAID users [22].
Nevertheless, we believe our study population to be repre-
sentative of Japanese NSAID users, given that the baseline
rate of dyspeptic symptoms was generally comparable tothe reported incidence in a recent meta-analysis of NSAID
treatment studies of osteoarthritis patients in Japan [23].
This difference may be important when interpreting
the dyspeptic symptom findings during long-term
esomeprazole therapy.
A strength of the present study was that it used endo-
scopic endpoints rather than surrogate markers of peptic
ulcer recurrence, such as symptom relapse. Frequent
endoscopic assessment also served to ensure that the at-
risk study population was closely monitored for prompt
detection of ulcer recurrence. Another strength is that
concomitant use of mucosal protectants such as gefarnate,
which are frequently used in Japan to reduce the risk of
peptic ulcers with NSAID therapy, was not permitted.
This helped to ensure that the true gastroprotective effect
of esomeprazole was observed, without confounding by
the moderate efficacy of mucosal protection noted in com-
parable long-term studies [18]. The lack of a placebo or
active treatment comparator could be considered a study
limitation, although use of a placebo arm would be uneth-
ical in a study population at high risk of ulcer recurrence.
Moreover, the existence of an extensive published litera-
ture on esomeprazole in long-term NSAID users allows
some historical comparisons to be made. Indeed, findings
in the present Japanese population are in agreement with
results from other populations [12,13]. Another limitation
is that compliance was measured by returned capsule
counting and NSAID diaries. While this was the only feas-
ible option in the current study, we have to accept the lim-
itations of such an approach for evaluating compliance.
The small size of the study also has to be considered, as
this precludes the precise evaluation of rare AEs such as
fracture. Indeed, there has been concern about the moder-
ately elevated risk of fracture (hip, spine and wrist) with
PPI long-term therapy based on a recent meta-analysis of
observational studies [24]. However, the underlying bio-
logical mechanism(s) behind this increased risk remain
unclear, and only 3 patients experienced a fracture (hand
finger, rib and upper arm) in the present long-term study;
in all cases the event was not considered to be related to
the study drug. Concerns have also been raised about the
increased risk of pneumonia with long-term PPI therapy
in some [25] but not all [26] studies, although only 1 pa-
tient experienced such an event that was considered
possibly-related to study drug in the present investigation.
Larger studies of PPI therapy in at-risk NSAID users will
be required to explore the risk of these rare AEs in greater
detail.
Conclusions
In according with previous findings, esomeprazole
20 mg od had a favourable safety profile and was effica-
cious at preventing ulcer recurrence during long-term
treatment in Japanese NSAID users with a history of
Sugano et al. BMC Gastroenterology 2013, 13:54 Page 8 of 9
http://www.biomedcentral.com/1471-230X/13/54peptic ulcer. Moreover, modified LANZA scores of the
severity of gastric mucosal lesions were generally im-
proved and few patients reported dyspeptic symptoms,
consistent with the gastroprotective efficacy of esome-
prazole in this population.
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